Peluntamig (PT-217) is a bispecific antibody targeting DLL3 and CD47. The antibody arms of Peluntamig specifically bind to DLL3 on small cell lung cancer tumor cells while blocking the CD47-SIRPa interaction, thereby effectively stimulating macrophage phagocytosis and inducing NK cell-mediated cytotoxicity. Peluntamig exhibits significant anti-tumor activity against small cell lung cancer and also has favorable safety profiles. Peluntamig can be used in a variety of tumor-related studies including those on small cell lung cancer and L1210 leukemia[1][2].
Purity:
99.9
CAS Number:
[2928515-21-1]
Target:
CD47
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
